ART 6043
Alternative Names: ART-6043Latest Information Update: 24 Jul 2023
At a glance
- Originator Artios Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 30 Jun 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT05898399)
- 30 Jun 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO) (NCT05898399)
- 15 Jun 2023 Preclinical trials in Solid tumours in United Kingdom (PO)